Evaluation the Effect of Chemotherapy Drugs and Thiosemicarbazone Complexes on the Expression of URHC and CASC15 LncRNAs in Acute Lymphoblastic Leukemia Cell Line 2 2 Background: Acute lymphoblastic leukemia (ALL) is a common type of leukemia in children, accounting for about 30% of pediatric malignancies. Researchers aimed to assess the impact of chemotherapy drugs and Thiosemicarbazone complexes on the expression of URHC and CASC15 LncRNAs in Jurkat E6.1 cell line, which represents Acute Lymphoblastic Leukemia. Thiosemicarbazone complexes are a group of chemical compounds known for their antitumor activities. Material and Methods: Optimal doses of chemotherapy drugs and thiosemicarbazone complexes were prepared and administered to the cell line at different time points (24, 48, and 72 hours). RNA extraction and cDNA synthesis were performed, and the expression of URHC, CASC15, and GAPDH genes was measured using Real-time PCR. Statistical analysis was conducted on the obtained results. Results: The study found that complex 3, a combination of two chemotherapy drugs (Cytarabine and 6MP) at specific concentrations (1 mM and 5 mM, respectively), significantly reduced the expression of URHC after 72 hours. Similarly, treatment with Arac at 5 mM for 72 hours showed the most effective concentration and time for decreasing the expression of CASC15 LncRNAs. Conclusion: In conclusion, the research demonstrated that the studied drugs had a positive impact on reducing the expression of CASC15 and URHC onco-lncRNAs. However, the optimal effects varied depending on the concentrations and treatment durations. These findings highlight the potential of the examined drugs in targeting specific LncRNAs associated with Acute Lymphoblastic Leukemia. 1 9 2023/01/10 1401/10/20 2023/03/12 1401/12/21 Arezoo Hassani Arezoo Hassani Department of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran harezoo89@gmail.com Golnaz Asaadi Tehrani Golnaz Asaadi Tehrani Department of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran Golnaz_ asaadi¬ @yahoo.com Neda Zahmatkesh Neda Zahmatkesh Department of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran zahmatkeshneda@yahoo.com Sina Mirzaahmadi Sina Mirzaahmadi Department of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran sinacanmir@yahoo.com Acute lymphoblastic leukemia Chemotherapy Thiosemicarbazone lncRNA ## ##

A case of Kikuchi–Fujimoto Disease in a SLE patient; potential importance of OR8U8 gene polymorphisms 2 2 Background: A Kikuchi–Fujimoto Disease (KFD) is a benign, self-limiting lymphadenopathy condition which mostly diagnosed by a pathologist due to a lymph node biopsy. In this study, we tried to report a case of KFD in a 38-year-old Iranian woman. Furthermore, an evaluation of some genetic polymorphisms in the patient’s peripheral blood was performed. Case presentation: The patient was a 38-year-old female with a background of systemic lupus erythematosus, hypertension, hypothyroidism, and type 2 diabetes. The patient was under antibiotic treatment which was without any results. So she was referred to the rheumatology department for more evaluation. The patient went through various tests, Furthermore, the lymph node biopsy confirmed KFD. We could not find the EBV genome in the patient’s serum. The polymorphisms evaluation revealed wild-type alleles in all rs78460947 in OR8U8, rs34068039 in RIOX1, rs2799077 in ZSCAN26, and rs2273346 in MASP-2 but some other polymorphisms in OR8U8 gene. Patient treatment was performed by the lymph node excision during sampling and anti-inflammation. Conclusion: KFD is a rare disease in Iranian patients. No specific Polymorphisms could be found in this study in KFD except in the OR8U8 gene. Further evaluation of these polymorphisms provides a diagnostic or prognostic tool for KFD by more comprehensive studies. 10 16 2023/01/102023/01/21 1401/11/1 2023/03/122023/03/24 1402/1/4 Ali Gholami Ali Gholami School of Medicine, Arak University of Medical Sciences, Arak, Iran dr.ali.gholami.arak@gmail.com Baharak Tasorian Baharak Tasorian Department of Rheumatology, Arak University Of Medical Sciences, Arak, Iran bhrktsn2002@gmail.com Amir Vard Amir Vard Department of pathology, Arak University of Medical Sciences alirezatabibzadeh@gmail.com Parastoo Yousefi Parastoo Yousefi Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran parastoo_y@yahoo.com Alireza Tabibzadeh Alireza Tabibzadeh Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran alireza.tabibzadeh@outlook.com Kikuchi–Fujimoto Disease lymphadenopathy Systemic lupus erythematosus ## ##

Right ventricular thrombus in a child with aluminum phosphide poisoning: A case report and review of the literature 2 2 Background: Aluminum phosphide (ALP) is a highly toxic inorganic compound used as a rodenticide, insecticide, and fumigant for stored cereal grains. Sometimes it uses for suicidal or criminal purposes, due to the low cost and availability of this tablet.Cardiovascular involvement is common and is the leading cause of death in these patients, but intra-cardiac thrombosis is rare and more common in the left ventricle following left ventricular dysfunction. The aim of our work was to describe an atypical manifestation of cardiovascular involvement of ALP poisoning. Case presentation: We report a case of an ALP-poisoned child, with the uncommon complications of mobile right ventricular thrombus who has been treated successfully with systemic thrombolysis. An eleven year- old boy who referred to us with unstable hemodynamic status after suicidal ingestion of 3 grams ALP tablet. To the best of our knowledge, he is the first case of right ventricular thrombosis in the setting of ALP poisoning in the English literature. Conclusion: In this ALP-poisoned child case, systemic thrombolysis along with conservative management could save the child from a non-reported complication of ALP. 17 21 2023/01/102023/01/212023/01/21 1401/11/1 2023/03/122023/03/242023/03/24 1402/1/4 Mehdi Sheibani Mehdi Sheibani Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran mesheibani@yahoo.com Fariba Farnaghi Fariba Farnaghi Department of Pediatrics, Loghman Hakim Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran faribafarnaghi@yahoo.com Parastoo Molaei Tavana Parastoo Molaei Tavana Department of Pediatrics, Loghman Hakim Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran dr_p1984@yahoo.com Nargea Gholami Nargea Gholami Department of Pediatrics, Loghman Hakim Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran nargesgholami724@yahoo.com Hossein Hassanian-Moghaddam Hossein Hassanian-Moghaddam Department of Clinical Toxicology, Loghman Hakim Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran hasanian2000@yahoo.com Aluminum phosphide Right ventricular thrombosis Systemic thrombolysis ## ##

The effect of Vitamin E and N-acetyl cysteine on oxidative status and hemoglobin level in transfusion-dependent thalassemia patients: A systematic review and meta-analysis 2 2 Background: This meta-analysis was conducted to summarize the comparative effect of Vitamin E and N-acetyl cysteine (NAC) on oxidative status, including total antioxidant capacity (TAC), total oxidative stress (TOS), oxidative stress index (OSI), and hemoglobin (Hb) in patients with TDT. Methods: This systematic review and meta-analysis was done according to the PRISMA checklist. We searched databases including Web of Science (ISI), Scopus, Medline (via PubMed), and Embase. Meta-analysis was done using Stata statistical software version 16.0. Results: Finally, four randomized-controlled trials (RCT) for Vitamin E and three RCTs for NAC were included. Our meta-analyses and review showed a significant increase in the weighted mean differences (WMD) of Hb and a significant decrease in the WMD of TOS and OSI in children subgroup of Vitamin E. Also, based on the results of the review in the NAC group, a significant increase in the WMD of Hb and a significant decrease in the WMD of TOS and OSI were found in children. Conclusions: Vitamin E showed a beneficial effect on improving anemia in TDT children. Moreover, both NAC and Vitamin E seems to be effective antioxidant supplements in children with TDT. More well-designed randomized, controlled trials for the effect of NAC and Vitamin E in TDT patients are recommended with more focus on the essential influencing factors on the oxidative status in these patients. ./files/site1/files/Suppelementary_1.docx . ./files/site1/files/Suppelementary_2.docx 22 35 2023/01/102023/01/212023/01/212023/01/4 1401/10/14 2023/03/122023/03/242023/03/242023/02/28 1401/12/9 Sezaneh Haghpanah Sezaneh Haghpanah Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran haghpanah@sums.ac.ir Mahnaz Hosseini-Bensenjan Mahnaz Hosseini-Bensenjan Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran m.hosseyni42@gmail.com Omid reza Zekavat Omid reza Zekavat Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran ozekavat@gmail.com Mohammadreza Bordbar Mohammadreza Bordbar Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran mbordbar53@gmail.com Mehran Karimi Mehran Karimi Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran mkarimi820@gmail.com Mani Ramzi Mani Ramzi Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran ramzim43@yahoo.com Naeimehossadat Asmarian Naeimehossadat Asmarian Anesthesiology and Critical Care Research Center, Shiraz University of Medical Science, Shiraz, Iran shirinparand47@gmail.com Acetyl cysteine Meta-Analysis Transfusion-dependent thalassemia Vitamin E ## ##

Angioimmunoblastic T-cell lymphoma associated with leukocytosis and lymphocytosis; a case report and systematic review 2 2 Background: Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon lymphoma arising from follicular T-helper cells. Since this is a rare disease, diagnosis is unfortunately difficult. AITL responds to treatments, therefore by reviewing the characteristics of the available cases, we aimed to classify the available data for in-time diagnosis. Objectives and data sources: A systematic search was performed on PubMed, Scopus, and Web of Science to January 5, 2023, to investigate the presence of peripheral blood lymphocytosis and leukocytosis in AITL cases. Results: Among 129 papers, 41 articles with 46 cases were included. All 41 studies were checked in terms of quality by two independent reviewers using an eight-item Joanna Briggs Institute checklist for case report studies. We also reported a 57-year-old Iranian woman with AITL suspected rash. Complete blood count (CBC) analysis showed a significant lymphocytosis and leukocytosis of 26 and 37.5 × 109 /L, respectively. Conclusion: In the reviewed cases, male predominance was obvious. Lymphadenopathy was the most seen clinical presentation. Dermal abnormalities were presented in more than half of the patients. The prevalence of blood eosinophilia was also remarkable; CD3 and CD4 were expressed the most and CD7, CD8, CD30, and CD56 the least. Despite treatment, the mortality rate was high. In this systematic review, we tried to provide a complete classified review of all AITL cases with different types of leukocytosis to avoid future miss diagnosis of this rare lymphoma. 36 52 2023/01/102023/01/212023/01/212023/01/42023/02/19 1401/11/30 2023/03/122023/03/242023/03/242023/02/282023/03/17 1401/12/26 Esmaeil Shahabi Satlsar Esmaeil Shahabi Satlsar Clinical laboratory sciences department, School of Paramedical Sciences, Guilan University of Medical Sciences, Rasht, Iran esmaeilshahabi@yahoo.com Saeid Anvari Saeid Anvari Regenerative medicine, organ procurement and transplantation multi-disciplinary center, Razi hospital, school of medicine, Guilan university of medical sciences, Rasht, Iran; drsaeidanvari@gmail.com drsaeidanvari@gmail.com Fatemeh Sotoudeh Fatemeh Sotoudeh Student research committee, school of paramedical sciences, Guilan university of medical sciences, Rasht, Iran f.sotoudeh.2000@gmail.com Seyed Hossein Mirpour Hassankiadeh Seyed Hossein Mirpour Hassankiadeh Department of Internal Medicine, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran; mirhossein07@yahoo.com Amirhossein Rastgar Amirhossein Rastgar Department of Hematology and Blood Banking, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran amirhosseinrastgar74@gmail.com Setare Kheyrandish Setare Kheyrandish Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran 7masterstar@gmail.com Angioimmunoblastic T-cell lymphoma Immunoblastic Lymphadenopathy Leukocytosis Lymphocytosis Mehrpouri M, Pourbagheri-Sigaroodi A, Bashash D. The contributory roles of histone deacetylases (HDACs) in hematopoiesis regulation and possibilities for pharmacologic interventions in hematologic malignancies. International Immunopharmacology. 2021;100:108114.##Adam MNM, Adam MNM, Idris AAA, Ali ASM, Khalid IO. A rare diagnostic case of angioimmunoblastic T-cell lymphoma: . Science Progress and Research (SPR). 2022;2(1):414-8.##Shin WY, Bang HI, Kim J-A, Kim J, Park R. Angioimmunoblastic T-Cell Lymphoma with Polyclonal Proliferation of Plasma Cells: A Cautionary Note for Flow Cytometry Interpretations. Korean Journal of Clinical Laboratory Science. 2022;54(1):68-72.##Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBdO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720-48.##Jain G, Kumar C, Malhotra A, Mallick SR, Bakhshi S, Chopra A. Peripheral blood involvement in angioimmunoblastic T-cell lymphoma: A case report and review of the literature. American Journal of Blood Research. 2020;10(5):257.##Xie Y, Jaffe ES. How I diagnose angioimmunoblastic T-cell lymphoma. American Journal of Clinical Pathology. 2021;156(1):1-14.##Džeko Škugor N, Perić Z, Vrhovac R, Radić-Krišto D, Kardum-Skelin I, Jakšić B. Diffuse Large B-cell Lymphoma in Patient after Treatment of angioimmunoblastic T-cell Lymphoma. Collegium antropologicum. 2010;34(1):241-5.##Ferran M, Gallardo F, Baena V, Ferrer A, Florensa L, Pujol RM. The 'deck chair sign'in specific cutaneous involvement by angioimmunoblastic T cell lymphoma. Dermatology. 2006;213(1):50-2.##Hori H, Tanaka Y, Nakayama R, Nohgawa M. CD56-positive Angioimmunoblastic T-cell Lymphoma Complicated by Chylothorax. Internal Medicine. 2022;61(5):729-33.##Swarup S, Kopel J, Thein KZ, Tarafdar K, Swarup K, Thirumala S, Quick DP. Sequential Complications of Hypercalcemia, Necrotizing Granulomatous Vasculitis, and Aplastic Anemia Occurring in One Patient with Angioimmunoblastic T-cell Lymphoma. The American journal of the medical sciences. 2021;361(3):375-82.##Wawrzycki B, Prystupa A, Szumiło J, Panasiuk L, Krasowska D. Fever, rash, and eosinophilia-early signs of angioimmunoblastic T-cell lymphoma. Annals of Agricultural and Environmental Medicine. 2021;28(3):525.##Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann T, Mulrow CD, Shamseer L, Moher D. Mapping of reporting guidance for systematic reviews and meta-analyses generated a comprehensive item bank for future reporting guidelines. Journal of clinical epidemiology. 2020;118:60-8.##Mohammed Saleh MF, Kotb A, Abdallah GE, Muhsen IN, El Fakih R, Aljurf M. Recent Advances in Diagnosis and Therapy of Angioimmunoblastic T Cell Lymphoma. Current Oncology. 2021;28(6):5480-98.##McBride AB, Porcu P. The rise of a new "great teacher". Blood, The Journal of the American Society of Hematology. 2021;138(3):205-6.##Nguyen PN, Tran NT, Nguyen TP, Ngo TN, Van Lai D, Deel CD, Hassell LA, Vuong HG. Clinicopathological Implications of RHOA Mutations in Angioimmunoblastic T-Cell Lymphoma: A Meta-analysis: RHOA mutations in AITL. Clinical Lymphoma Myeloma and Leukemia. 2021;21(7):431-8.##Horesh N, Horowitz NA. Does gender matter in non-Hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy. Rambam Maimonides medical journal. 2014;5(4).##Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harbor perspectives in biology. 2014;6(10):a016295.##Chiba S, Sakata-Yanagimoto M. Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia. 2020;34(10):2592-606.##Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood, The Journal of the American Society of Hematology. 2017;129(9):1095-102.##Jeong J, Yu JE, Choi YD, Kim SK, Yoon W, Koh Y-I. Differentiation of angioimmunoblastic T-cell lymphoma from DRESS syndrome. The Journal of Allergy and Clinical Immunology: In Practice. 2019;7(5):1684-6. e1.##Burns EA, Anand K, Chung B, Shah S, Randhawa JK, Pingali SR. The development of T-cell malignancies in patients with pre-existing myeloproliferative neoplasms: a report of three cases. ecancermedicalscience. 2020;14.##Kanderi T, Goel S, Shrimanker I, Nookala VK, Singh P. Angioimmunoblastic T-cell Lymphoma: An Unusual Case in an Octogenarian. Cureus. 2020;12(2).##Kuroda K, Tambe A, Iftikhar R, Nat AS, Basnet A. A Case of Angioimmunoblastic T-cell Lymphoma That Mimics As Autoimmune Diseases and Infections. Cureus. 2021;13(7).##Genovesi-Ebert A, Lombardi M, Capochiani E, Simi U, Savoia MT, Baldini U, Digiorgio A, Carluccio M, Di Santo D, Galli M. Heart involvement in T cell lymphoma through hypereosinophilic syndrome: a common complication of a rare condition. Journal of Cardiovascular Magnetic Resonance. 2005;7(2):495-9.##Yabe M, Dogan A, Horwitz SM, Moskowitz AJ. Angioimmunoblastic T-cell lymphoma. T-Cell and NK-Cell Lymphomas. 2019:99-126.##Lee WJ, Won KH, Choi JW, Won CH, Chang SE, Choi JH, Lee MW. Cutaneous angioimmunoblastic T-cell lymphoma: Epstein-Barr virus positivity and its effects on clinicopathologic features. Journal of the American Academy of Dermatology. 2019;81(4):989-97.##Ahsanuddin AN, Brynes RK, Li S. Peripheral blood polyclonal plasmacytosis mimicking plasma cell leukemia in patients with angioimmunoblastic T-cell lymphoma: report of 3 cases and review of the literature. International Journal Of Clinical and Experimental Pathology. 2011;4(4):416.##Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A, Meijer CJ, Emile J-F, Bouabdallah R, Bosly A. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood, The Journal of the American Society of Hematology. 2008;111(9):4463-70.##Gabali A. Flow cytometry, molecular analysis, and other special techniques (in Serous Fluid Cytopathology). CytoJournal. 2022;19.##Loghavi S, Wang SA, Jeffrey Medeiros L, Jorgensen JL, Li X, Xu-Monette ZY, Miranda RN, Young KH. Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. Leukemia & lymphoma. 2016;57(12):2804-12.##Satoh T, Kayano H, Takahashi N, Tsukasaki K, Yasuda M. Diagnostic utility of the aberrant immunohistochemical expression of CD3 molecules for peripheral T-cell lymphomas. Annals of Diagnostic Pathology. 2022;60:152013.##Baseggio L, Berger F, Morel D, Delfau-Larue M, Goedert G, Salles G, Magaud J, Felman P. Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma. Leukemia. 2006;20(2):296-303.##Patel BK, Basu D, Kar R, Dubashi B. Immunophenotyping of Nodal Peripheral T-cell Lymphomas and its Association with Epstein-Barr Virus. Iranian Journal of Blood and Cancer. 2019;11(3):101-8.##Chen N, Amber S. Eosinophilia and Cutaneous Involvement in Angioimmunoblastic T-Cell Lymphoma. Journal of Allergy and Clinical Immunology. 2016;137(2, Supplement):AB169-AB70.##Hapgood G, Mottok A, Slack GW, Gascoyne RD, Steidl C, Savage KJ, Weng AP. Flow Cytometric Characterization of 129 Cases of Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL NOS) and Angioimmunoblastic T Cell Lymphoma (AITL). Blood. 2015;126(23):2667.##Satou A, Takahara T, Tsuzuki T. Pathological and Molecular Features of Nodal Peripheral T-Cell Lymphomas. Diagnostics. 2022;12(8):2001.##Bahmani F, Azadpour S, Pourbagheri-Sigaroodi A, Bashash D. Plant-derived natural compounds as promising anticancer agents in hematological malignancies. Iranian Journal of Blood and Cancer. 2022;14(3):57-70.##SAHU S, DONGRE N. A Review on Analytical Method Development and Validation of Cyclophosphamide.##Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. Journal of pharmacy and pharmacology. 2013;65(2):157-70.##Avendano C, Menendez JC. Anticancer drugs targeting tubulin and Microtubules. Medicinal Chemistry of Anticancer Drugs Elsevier, Boulevard. 2015:359-87.##Puckett Y, Gabbar A, Bokhari AA. Prednisone. 2018.##Moskowitz AJ. Practical treatment approach for angioimmunoblastic T-cell lymphoma. Journal of oncology practice. 2019;15(3):137-43.##Yoon SE, Cho J, Kim YJ, Kim SJ, Kim WS. Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2022;22(11):e972-e80.## ##

Serum visfatin level as a prognostic marker in colorectal cancer patients: A retrospective cohort study 2 2 Background: Colorectal cancer is the third common cancer in women and the fourth one among men, worldwide. Identifying prognostic factors are among the current challenges in cancer management. There are some evidence that visfatin, an adipocyte-secreted peptide, plays a significant role in cancer progression, proliferation, angiogenesis, metastasis, and drug resistance. In this study, we examined the serum concentration of visfatin and its impact on colorectal cancer prognosis. Methods: Sixty-nine colorectal patients who had been followed up for two years at Razavi Hospital, Mashhad, Iran were evaluated. Information regarding the patients’ cancer status, including primary tumor location, tumor size, histology, tumor differentiation, stage of TNM, metastasis or lymphatic invasion, treatment options over the past two years, as well as the disease status, including recurrences and survival, was collected. An ELISA kit was used to measure serum visfatin concentrations and the relationship between serum visfatin concentrations and the prognosis of colorectal cancer was examined using SPSS software. Results: Visfatin played a small role in death, metastasis, and recurrence of colorectal cancer. Additionally, Cox regression analysis revealed no significant relationship between death, metastasis and recurrence rate and visfatin concentration (p>0.05). Additionally, no significant difference in visfatin concentration was found between two genders. Conclusion: The results of this study showed that according to survival analysis and Cox regression, there was no significant association between serum concentration of visfatin and death, metastasis, or recurrence in colorectal cancer.So, visfatin does not seem a good biomarker for colorectal cancer prognosis prediction. Further studies are recommended. 53 59 2023/01/102023/01/212023/01/212023/01/42023/02/192023/01/10 1401/10/20 2023/03/122023/03/242023/03/242023/02/282023/03/172023/02/24 1401/12/5 Amir Hooshang Mohammadpour Amir Hooshang Mohammadpour Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran mohamadpoorah@mums.ac.ir Kamran Ghaffarzadegan Kamran Ghaffarzadegan Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran kghafarzadegan@hotmail.com Ranna Raygani Ranna Raygani Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran rayganir@mums.ac.ir Azra Izanloo Azra Izanloo Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran a.izanloo64@gmail.com Soghra Mehri Soghra Mehri Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran Mehris@mums.ac.ir Mahdi Jannati Mahdi Jannati Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran jannatim971@mums.ac.ir Sepideh Elyasi Sepideh Elyasi Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran elyasis@mums.ac.ir Visfatin Colorectal cancer Prognostic marker Survival ## ##

CRISPR/Cas9 technology: A promising gene-editing tool for the treatment of cancers 2 2 Clustered Regularly Interspaced Palindromic Repeats (CRISPR) technology is an innovative gene-editing technique that has emerged as a result of the development of genetic engineering. This technology has expanded the scope of oncology-related medical research and clinical applications. CRISPR is used in molecular techniques to decode genes and pathways, alter the expression of specific genes for therapeutic purposes, and comprehend the pathophysiology of cancer. If pre-clinical research with this technology is successful, it could lead to clinical trials and eventually be used in clinical therapy. To establish the CRISPR complex as a promising tool in oncology for effective clinical cancer therapy, a variety of CRISPR variants and applications, as well as numerous experimental techniques, are being developed at present. This review examines several CRISPR technology variations, their application in oncology, as well as the system's advantages and disadvantages in comparison to earlier gene-editing technologies. It also discusses the recently discovered capabilities of the technology and its potential future applications in oncology. 60 70 2023/01/102023/01/212023/01/212023/01/42023/02/192023/01/102022/12/30 1401/10/9 2023/03/122023/03/242023/03/242023/02/282023/03/172023/02/242023/03/2 1401/12/11 Muhammad Khairi Ahmad Muhammad Khairi Ahmad Department of Biomedical Sciences, Advanced Medical and Dental Institute, Sains@Bertam, Universiti Sains Malaysia, 13200 Kepala Batas, Pulau Pinang, MALAYSIA. Kumitaa Theva Das Kumitaa Theva Das Department of Biomedical Sciences, Advanced Medical and Dental Institute, Sains@Bertam, Universiti Sains Malaysia, 13200 Kepala Batas, Pulau Pinang, MALAYSIA. Siti Razila Abdul Razak Siti Razila Abdul Razak Department of Biomedical Sciences, Advanced Medical and Dental Institute, Sains@Bertam, Universiti Sains Malaysia, 13200 Kepala Batas, Pulau Pinang, MALAYSIA. sitirazila@usm.my CRISPR technology Gene editing Cancer Oncology Molecular research Clinical application Francisco J. M. Mojica FR-V. The discovery of CRISPR in archaea and bacteria. The FEBS Journal. 2016;283(17):3162-9.##Rodolphe Barrangou PH. A decade of discovery: CRISPR functions and applications. Nature Microbiology. 2017;2.##Fyodor D. Urnov EJR, Michael C. Holmes, H. Steve Zhang, Philip D. Gregory. Genome editing with engineered zinc finger nucleases. Nature Reviews Genetics. 2010;11:636-46.##A A Nemudryi KRV, S P Medvedev, S M Zakian TALEN and CRISPR/Cas Genome Editing Systems: Tools of Discovery. Acta Naturae. 2014;6(3):19-40.##Kasey Rodgers MM. Error‐prone repair of DNA double‐strand breaks. Journal of Cellular Physiology. 2016;231(1):15-24.##F Ann Ran PDH, Jason Wright, Vineeta Agarwala, David A Scott, Feng Zhang. Genome engineering using the CRISPR-Cas9 system. Nature Protocols. 2013;8(11):2281-308.##Tautvydas Karvelis GG, Algirdas Miksys, Rodolphe Barrangou, Philippe Horvath, Virginijus Siksnys crRNA and tracrRNA guide Cas9-mediated DNA interference in Streptococcus thermophilus. RNA Biology. 2013;10(5):841-51.##Tomas Sinkunas GG, Christophe Fremaux, Rodolphe Barrangou, Philippe Horvath, Virginijus Siksnys. Cas3 is a single‐stranded DNA nuclease and ATP‐dependent helicase in the CRISPR/Cas immune system. The EMBO Journal. 2011;30(7):1335-42.##Migle Kazlauskiene. GK, Česlovas Venclovas, Gintautas Tamulaitis, Virginijus Siksnys. A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems. Science. 2017;357(6351):605-9.##Ling Wang CYM, Michael R. Wasserman, Jakob T. Rostøl, Luciano A. Marraffini, Shixin Liu. Dynamics of Cas10 govern discrimination between self and Non-self in type III CRISPR-Cas immunity. Molecular Cell. 2019;73(2):278-90.e4.##Ahsen Özcan PP, Andreas Linden, Alexander Wulf, Karola Schühle, Johann Heider, Henning Urlaub, Thomas Heimerl, Gert Bange & Lennart Randau. Type IV CRISPR RNA processing and effector complex formation in Aromatoleum aromaticum. Nature Microbiology. 2018;4(89-96).##Kira S Makarova YIW, Omer S Alkhnbashi, Fabrizio Costa, Shiraz A Shah, Sita J Saunders, Rodolphe Barrangou, Stan J J Brouns, Emmanuelle Charpentier, Daniel H Haft, Philippe Horvath, Sylvain Moineau, Francisco J M Mojica, Rebecca M Terns, Michael P Terns, Malcolm F White, Alexander F Yakunin, Roger A Garrett, John van der Oost, Rolf Backofen, Eugene V Koonin An updated evolutionary classification of CRISPR-Cas systems. Nature reviews Microbiology. 2015;13(11):722-36.##Felicity Allen LC, Clara Alsinet, Alexander J Strong, Vitalii Kleshchevnikov, Pietro De Angeli, Petra Páleníková, Anton Khodak, Vladimir Kiselev, Michael Kosicki, Andrew R Bassett, Heather Harding, Yaron Galanty, Francisco Muñoz-Martínez, Emmanouil Metzakopian, Stephen P Jackson, Leopold Parts. Predicting the mutations generated by repair of Cas9-induced double-strand breaks. Nature Biotechnology. 2018;10.1038/nbt.4317.##Xing Zhu RC, Anupama K. Puppala, Sagar Chittori, Alan Merk, Bradley J. Merrill, Miljan Simonović, Sriram Subramaniam. Cryo-EM structures reveal coordinated domain motions that govern DNA cleavage by Cas9. Nature. 2019;26:679-85.##Fatemeh Safari KZ, Manica Negahdaripour, Mazyar Barekati-Mowahed, Younes Ghasemi CRISPR Cpf1 proteins: structure, function and implications for genome editing. Cell & Bioscience. 2019;9(36).##O'Connell MR. Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR-Cas Systems. Journal of Molecular Biology. 2019;4(431):66-87.##David B T Cox JSG, Omar O Abudayyeh, Brian Franklin, Max J Kellner, Julia Joung, Feng Zhang. RNA editing with CRISPR-Cas13. Science. 2017;358(6366):1019-27.##Haoyi Wang HY, Chikdu S Shivalila, Meelad M Dawlaty, Albert W Cheng, Feng Zhang, Rudolf Jaenisch. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013;4:910-8.##Service RF. Modified CRISPR cuts and splices whole genomes. Science. 2019;365(6456):849.##Adam E. Dolan ZH, Yibei Xiao, Max J. Gramelspacher, Jaewon Heo, Sara E., Howden PLF, Ailong Ke, and Yan Zhang. Introducing a spectrum of long-range genomic deletions in human embryonic stem cells using type I CRISPR-Cas Molecular Cell. 2019;74.##Xiao-Hui Zhang LYT, Xiao-Gang Wang, Qun-Shan Huang, Shi-Hua Yang. Off-target effects in CRISPR/Cas9-mediated genome engineering. Molecular therapy Nucleic acid. 2015;4(11):e264.##Xueli Tian TG, Satyananda Patel, Ann M Bode, Mee-Hyun Lee, Zigang Dong CRISPR/Cas9-An evolving biological tool kit for cancer biology and oncology. NPJ precision medicine. 2019;3(8).##Tianzuo Zhan NR, Johannes Betge, Matthias P Ebert, Michael Boutros. CRISPR/Cas9 for cancer research and therapy. Seminars in Cancer Biology. 2018;55:106-19.##Le Cong FAR, David Cox, Shuailiang Lin, Robert Barretto, Naomi Habib, Patrick D Hsu, Xuebing Wu, Wenyan Jiang, Luciano A Marraffini, Feng Zhang. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819-23.##Prashant Mali LY, Kevin M Esvelt, John Aach, Marc Guell, James E DiCarlo, Julie E Norville, George M Church. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823-6.##Cyranoski D. Chinese scientists to pioneer first human CRISPR trial. Nature. 2016;535:476-7.##Esmaeili S, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, Salari S, Gharehbaghian A, Hamidpour M, Bashash D. Stimulation of peroxisome proliferator-activated receptor-gamma (PPARγ) using pioglitazone decreases the survival of acute promyelocytic leukemia cells through up-regulation of PTEN expression. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2021;21(1):108-19.##Xu L, Wu H, Wu X, Li Y, He D. The expression pattern of Bcl11a, Mdm2 and Pten genes in B‐cell acute lymphoblastic leukemia. Asia‐Pacific Journal of Clinical Oncology. 2018;14(2):e124-e8.##Hansakul P, Aree K, Tanuchit S, Itharat A. Growth arrest and apoptosis via caspase activation of dioscoreanone in human non-small-cell lung cancer A549 cells. BMC complementary and alternative medicine. 2014;14(1):1-12.##Chandrasekher G, Sailaja D. Differential Regulation of Cyclin-Dependent Kinase Inhibitors p21cip (p21) and p27kip (p27) Expression by PI-3-Kinase (PI-3K)/Akt in Lens Epithelium. Investigative Ophthalmology & Visual Science. 2005;46(13):1899-.##Huang F-L, Yu S-J, Li C-L. Role of autophagy and apoptosis in acute lymphoblastic leukemia. Cancer Control. 2021;28:10732748211019138.##David L Porter BLL, Michael Kalos, Adam Bagg, Carl H June. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England Journal of Medicine. 2011;365(8):725-33.##James N Kochenderfer WHW, John E Janik, Mark E Dudley, Maryalice Stetler-Stevenson, Steven A Feldman, Irina Maric, Mark Raffeld, Debbie-Ann N Nathan, Brock J Lanier, Richard A Morgan, Steven A Rosenberg. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20).##Tang Y, Eng C. PTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner. Cancer research. 2006;66(2):736-42.##Florence Borot HW, Yan Ma, Toghrul Jafarov, Azra Raza, Abdullah Mahmood Ali, Siddhartha Mukherjee. Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies. Proceedings of the National Academy of Science of the United States of America. 2019;116(24):11978-87.##Hernandez-Quiles M, Broekema MF, Kalkhoven E. PPARgamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action. Frontiers in Endocrinology. 2021;12:624112.##Al-Alem L, Southard RC, Kilgore MW, Curry TE. Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner. PLoS One. 2011;6(1):e16179.##Malakouti P, Mohammadi M, Boshagh MA, Amini A, Rezaee MA, Rahmani MR. Combined effects of pioglitazone and doxorubicin on migration and invasion of MDA-MB-231 breast cancer cells. Journal of the Egyptian National Cancer Institute. 2022;34(1):1-10.##Moutal A YX, Li W, Gilbraith KB, Luo S, Cai S, François-Moutal L, Chew LA, Yeon SK, Bellampalli SS, Qu C, Xie JY, Ibrahim MM, Khanna M, Park KD, Porreca F, Khanna R. CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide. Pain. 2017;158(12):2301-19.##Saiki M, Hatta Y, Yamazaki T, Itoh T, Enomoto Y, Takeuchi J, Sawada U, Aizawa S, Horie T. Pioglitazone inhibits the growth of human leukemia cell lines and primary leukemia cells while sparing normal hematopoietic stem cells. International journal of oncology. 2006;29(2):437-43.##Zheng Hu 1 LY, Da Zhu 2, Wencheng Ding 2, Xiaoli Wang 2, Changlin Zhang 2, Liming Wang 2, Xiaohui Jiang 2, Hui Shen 2, Dan He 3, Kezhen Li 1, Ling Xi 1, Ding Ma 1, Hui Wang. Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells. Biomedical research international. 2014;2014:612823.##Takahiro Yoshiba YS, Masashi Urabe, Ryosuke Uchibori, Shigeki Matsubara, Hiroyuki Fujiwara, Hiroaki Mizukami. CRISPR/Cas9‑mediated cervical cancer treatment targeting human papillomavirus E6. Oncology Letters. 2019;17(2):2197-206.##Simioni C, Martelli AM, Zauli G, Vitale M, McCubrey JA, Capitani S, Neri LM. Targeting the phosphatidylinositol 3‐kinase/Akt/mechanistic target of rapamycin signaling pathway in B‐lineage acute lymphoblastic leukemia: An update. Journal of Cellular Physiology. 2018;233(10):6440-54.##Shu Su ZZ, Fangjun Chen, Naiqing Ding, Juan Du, Jie Shao, Lin Li, Yao Fu, Bian Hu, Yang Yang, Huizi Sha, Fanyan Meng, Jia Wei, Xingxu Huang, Baorui Liu. CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. Oncoimmunology. 2016;6(1):e1249558.##Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Phillip Koeffler H. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer research. 1998;58(15):3344-52.##Philippe Horvath RB. CRISPR/Cas, the immune system of bacteria and archaea. Science. 2010;327(5962):167-70.##Waller MC, Bober JR, Nair NU, Beisel CL. Toward a genetic tool development pipeline for host-associated bacteria. Curr Opin Microbiol. 2017;38:156-64.##Nouri Nayerossadat TM, Palizban Abas Ali. Viral and nonviral delivery systems for gene delivery. Advanced biomedical research. 2012;1(27).##Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 2018;25(1):1234-57.##Severine Loisel-Meyer TF, Jacopo Mariotti, Miriam E Mossoba, Jason E Foley, Robert Kammerer, Nobuo Mizue, Robert Keefe, J Andrea McCart, Wolfgang Zimmermann, Boro Dropulic, Daniel H Fowler, Jeffrey A Medin. Potent induction of B-and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection. Molecular cancer therapeutics. 2009;8(3):692-702.##Karine Breckpot DE, Frederick Arce, Lucienne Lopes, Katarzyna Karwacz, Sandra Van Lint, Marleen Keyaerts, Mary Collins. HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. Journal of virology. 2010;84(11):5627-36.##Vijayraghavan S, Kantor B. A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells. Jove-J Vis Exp. 2017(130).##Magdalena Hryhorowicz BG, Natalia Mazurkiewicz, Paweł Śledziński, Daniel Lipiński, Ryszard Słomski Improved delivery of CRISPR/Cas9 system using magnetic nanoparticles into porcine fibroblast. Molecular biotechnology. 2019;61(3):173-80.##Ji Liu JC, Ying Jiang, Xiandi Meng, Tianmeng Sun, Lanqun Mao, Qiaobing Xu, Ming Wang. Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible. Advanced materials. 2019;31(33):e1902575.##WHO. Human Genome editing [Available from: https://www.who.int/ethics/topics/human-genome-editing/en/.##Vogel KM. Crispr goes global: A snapshot of rules, policies, and attitudes Bulletin of the Atomic Scientists2018 [##Callaway E. UK scientists gain licence to edit genes in human embryos. Nature. 2016;530(18).##Cyranoski D. Japan set to allow gene editing in human embryos. Nature. 2018.##Grant EV. FDA Regulation of Clinical Applications of CRISPR-CAS Gene-Editing Technolog. Food and drug law journal. 2016;71(4):608-33.## ##

A review of the interaction between the coagulation system and cancer 2 2 Background: Interaction between cancer cells and the coagulation system could have reciprocal effects on both groups. Coagulation-fibrinolytic cascade is a process that regulates the homeostasis of the body, and this process can be disrupted by several factors; one of the most important factor is cancer. In contrast, the coagulation-fibrinolytic system can also act as a factor in cancer growth and metastasis. Our aim in this study is to investigate this relationship. Methods: The present study is based on Pubmed database information (2010- 2023) using the words “Cancer”, “Coagulation”, “Platelet “, “Tissue factor” and “ VTE “. Results: Cancer cells disrupt the coagulation process by activating prooncogenic factors or inhibiting tumor suppressors, thereby inducing changes in platelets and coagulation factors, and increasing proteins involved in coagulation. These aberrations in the coagulation system result in coagulation abnormalities such as venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC). In various cancers, the activity of the coagulation and fibrinolytic systems increases, leading to an increase in coagulation and fibrinolysis factors. These factors are closely related to tumor size, tumor stage, cancer progression and metastasis. Conclusions: The coagulation-fibrinolytic system is closely related to cancers.Cancer cells can disrupt the coagulation-fibrinolysis process. Also, coagulation-fibrinolytic agents can both lead to cancer progression and can be used as a marker for the prognosis of some cancers. 71 79 2023/01/102023/01/212023/01/212023/01/42023/02/192023/01/102022/12/302023/01/26 1401/11/6 2023/03/122023/03/242023/03/242023/02/282023/03/172023/02/242023/03/22023/03/17 1401/12/26 Najmaldin Saki Najmaldin Saki Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran najmaldinsaki@gmail.com Mohammadreza Javan Mohammadreza Javan Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Iranian Blood Transfusion Organization (IBTO), Tehran, Iran javaneee@gmail.com Mohammad Shokouhian Mohammad Shokouhian Department of Hematology and Blood Transfusion, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran mohammad.shokuhian@gmail.com Marzieh Bagheri Marzieh Bagheri Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran marziyebagheri6969@gmail.com Bahareh Moghimian-boroujeni Bahareh Moghimian-boroujeni Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran bahar.moghimian.74@gmail.com Cancer Coagulation Venous thromboembolism Platelet Tissue factor ## ##